EC Gastroenterology and Digestive System

Case Report Volume 9 Issue 11 - 2022

Tumors of the Gastrointestinal Stroma. Surgical Management and Tyrosinase Inhibitors (ITK)

Salvador Moreno Galeana1, Adrián Regalado Aquino2 and Juan Carlos Rivera Martínez3*

1Médico Residente de Cirugía General, Hospital de Especialidades Centro Médico Nacional La Raza, Ciudad de México, Mexico
2Médico Adscrito al Servicio de Cirugía General, Clínica de Cirugía de Organos Sólidos, Hospital de Especialidades Centro Médico Nacional La Raza, Ciudad de México, Mexico
3Médico Adscrito al Servicio de Cirugía General, Clínica de Intestino delgado, Hospital de Especialidades Centro Médico Nacional La Raza, Ciudad de México, Mexico

*Corresponding Author: Juan Carlos Rivera Martínez, Médico Adscrito al Servicio de Cirugía General, Clínica de Intestino delgado, Hospital de Especialidades Centro Médico Nacional La Raza, Ciudad de México, Mexico.
Received: February 17, 2021; Published: October 22, 2021



Gastrointestinal stromal tumors are tumors that can have a benign or malignant behavior. They originate from the interstitial cells of Cajal in the digestive tract. These entities have a slow growth and are recognized as a finding in imaging studies or in the intraoperative as a cause of intestinal occlusion, gastrointestinal bleeding or acute abdomen. Below we present two clinical cases with different presentations. The diagnosis is made with histopathology. Treatment of these tumors is essentially surgical, although it can be completed with targeted molecular therapy.

 

Keywords: GIST; Gastrointestinal Stromal Tumors; CD 117; Surgery; Tyrosine Kinase Inhibitors; Treatment

  1. Sanchez-Hidalgo JM., et al. “Gastrointestinal stromal tumors: A multidisciplinary challenge”. World Journal of Gastroenterology18 (2018): 1925-1941.
  2. Harlan LC., et al. “Gastrointestinal stromal tumors: treatment patterns of a population-based sample”. Journal of Surgical Oncology 111 (2015): 702-707.
  3. DeMatteo RP., et al. “Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival”. Annals of Surgery 231 (2000): 51-58.
  4. Rubin BP. “Gastrointestinal stromal tumours: an update”. Histopathology 48 (2006): 83-96.
  5. Pink D., et al. “Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases”. Journal of Clinical Oncology 23 (2005): 6809-6811.
  6. Maynard MA., et al. “Thyroid hormone inactivation in gastrointestinal stromal tumors”. The New England Journal of Medicine14 (2014): 1327-1334.
  7. Miettinen M., et al. “Tumores del estroma gastrointestinal en pacientes con neurofibromatosis 1: un estudio clínico-patológico y genético molecular de 45 casos”. International Journal of Surgical Pathology 30 (2006): 90-96.
  8. Díaz Delgado M., et al. “Tumores del estroma gastrointestinal múltiples no metastásicos: Aspectos diferenciales”. Revista Española de Enfermedades Digestivas8 (2010): 489-497.
  9. Janeway KA and Weldon CB. “Pediatric gastrointestinal stromal tumor”. Seminars in Pediatric Surgery 21 (2012): 31-43.
  10. Kamiyama Y., et al. “18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors”. World Journal of Surgery 29 (2005): 1429-1435.
  11. Hassanzadeh-Rad A., et al. “The value of (18) F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta-analysis”. European Journal of Gastroenterology and Hepatology 31 (2016): 929-935.
  12. Fletcher CD., et al. “Diagnosis of gastrointestinal stromal tumors: A consensus approach”. Human Pathology 33 (2002): 459-465.
  13. Eriksson M., et al. “Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?” European Journal of Cancer 59 (2016): 128-133.
  14. Everett M and Gutman H. “Surgical management of gastrointestinal stromal tumors: analysis of outcome with respect to surgical margins and technique”. Journal of Surgical Oncology 98 (2008): 588-593.
  15. Koga T., et al. “Necessity for resection of gastric gastrointestinal stromal tumors ≤ 20 mm”. Anticancer Research 35 (2015): 2341-2344.
  16. Andtbacka RH., et al. “Surgical resection of gastrointestinal stromal tumors after treatment with imatinib”. Annals of Surgical Oncology 14 (2007): 14-24.
  17. Bamboat ZM and DeMatteo RP. “Metastasectomy for gastrointestinal stromal tumors”. Journal of Surgical Oncology1 (2014): 23-27.
  18. Sugarbaker PH. “Sarcomatosis and Imatinib-Resistant GISTosis: Diagnosis and Therapeutic Options. Cytoreductive Surgery Perioperative Chemotherapy for Peritoneal Surface Malignancy Textbook and Video Atlas”. 1st ed. Woodbury, CT: Cine-Med Publishing, Inc (2012): 127-136.
  19. Ye YJ., et al. “Diagnosis and multi-disciplinary management of hepatic metastases from gastrointestinal stromal tumour (GIST)”. European Journal of Surgical Oncology 35 (2009): 787-792.
  20. Serralta AS., et al. “Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours”. European Journal of Gastroenterology and Hepatology 16 (2004): 1237-1239.
  21. Takaki H., et al. “Embolización de la arteria hepática para la metástasis hepática de un tumor del estroma gastrointestinal después de la terapia con imatinib y sunitinib”. Revista de Cáncer Gastrointestinal 4 (2014): 494-499.
  22. Joensuu H. “Risk stratification of patients diagnosed with gastrointestinal stromal tumor”. Human Pathology 39 (2008): 1411-1419.
  23. Hohenberger P., et al. “Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour”. British Journal of Surgery 97 (2010): 1854-1859.
  24. DeMatteo RP., et al. “Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial”. Annals of Surgery 3 (2013): 422-429.
  25. Von Mehren M and Joensuu H. “Gastrointestinal Stromal Tumors”. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2 (2018): 136-143.
  26. Waidhauser J., et al. “Frequency, localization, and types of gastrointestinal stromal tumor-associated neoplasia”. World Journal of Gastroenterology 30 (2019): 4261-4277.
  27. Akahoshi K., et al. “Current clinical management of gastrointestinal stromal tumor”. World Journal of Gastroenterology26 (2018): 2806-2817.
  28. Ahmed M. “Recent advances in the management of gastrointestinal stromal tumor”. World Journal of Clinical Cases15 (2020): 3142-3155.

Juan Carlos Rivera Martínez., et al. “Tumors of the Gastrointestinal Stroma. Surgical Management and Tyrosinase Inhibitors (ITK)”. ”. EC Gastroenterology and Digestive System  9.11 (2022): 24-28.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net